Cell line and drug-dependent effect of ERBB3 on cancer cell proliferation, chemosensitivity, and multidrug actions

References

• Leahy DJ. Structure and function of the epidermal growth factor (EGF/ ErbB) family of receptors. Adv Protein Chem. 2004;68:1–27.
   PubMedGoogle Scholar
• Lee D, Yu M, Lee T, et al. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest. 2009;119:2702–2713.
   PubMed Web of Science ®Google Scholar
• Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–452.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ERBB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137.
   PubMed Web of Science ®Google Scholar
• Yen L, Benlimame N, Nie ZR, et al. Differential regulation of tumor angiogenesis by distinct ERBB homo- and heterodimers. Mol Biol Cell. 2002;13:4029^044.
   Web of Science ®Google Scholar
• Soltoff SP, Carraway KL, III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14:3550–3558.
   PubMed Web of Science ®Google Scholar
• Kim HH, Sierke SL, Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the ERBB3 gene product. J Biol Chem. 1994;269:24747–24755.
   PubMed Web of Science ®Google Scholar
• Naidu R, Yadav M, Nair S, Kutty MK. Expression of C-ERBB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385–1390.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Kim N, Saeki T, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl AcadSci USA. 1991;88:7792–7796.
   PubMed Web of Science ®Google Scholar
• Maurer CA, Friess H, Kretschmann B, et al. Increased expression of ERBB3 in colorectal cancer is associated with concomitant increase in the level of ERBB2. Hum Pathol. 1998;29:771–777.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Iwamatsu A, Shinohara-Kanda A, Ihara S, Fukui Y. Activation of ERBB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene. 2003;22:1294–1301.
   Web of Science ®Google Scholar
• Jackson-Fisher A, Bellinger G, Breindel J, et al. ERBB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res. 2008;10:R96.
   Web of Science ®Google Scholar
• Hayashi M, Inokuchi M, Takagi Y, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14:7843–7849.
   PubMed Web of Science ®Google Scholar
• Koutras AK, Kalogeras KT, Dimopoulos MA, et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer. 2008;99:1775–1785.
   Web of Science ®Google Scholar
• Lin SH, Lee YC, Choveiri MB, et al. Soluble ERBB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008;14:3729–3736.
   Web of Science ®Google Scholar
• Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–448.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA, Mermel C, et al. ERBB3 mediates phospho-inositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005;102:3788–3793.
   PubMed Web of Science ®Google Scholar
• Rajkumar T, Stamp GW, Hughes CM, Gullick WJ. C-ERBB3 protein expression in ovarian cancer. Clin Mol Pathol. 1996;49:M199–M202.
   Google Scholar
• Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–1431.
   PubMed Web of Science ®Google Scholar
• Sergina NV Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–441.
   PubMed Web of Science ®Google Scholar
• Liu B, Ordonez-Ercan D, Fan Z, et al. Downregulation of ERBB3 abrogates ERBB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007;120:1874–1882.
   PubMed Web of Science ®Google Scholar
• Sergina NV Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13:527–534.
   Web of Science ®Google Scholar
• Cavallo MG, Pozzilli P, Misiti S, Baroni MG. Insulinoma CM cell line as in vitro model for beta-cell. J Cell Physiol. 2008;216:568.
   Web of Science ®Google Scholar
• Cavallo MG, Dolta F, Monetini L. Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. J Endocrinol. 1996;150:113–120.
   Web of Science ®Google Scholar
• Tanner B, Hasenclever D, Stevn K, et al. ERBB3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24:4317^323.
   Google Scholar
• Frolov A, Schuller K, Tzeng CW, et al. ERBB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther. 2007;6:548–554.
   PubMed Web of Science ®Google Scholar
• Davies GF, Juurlink BH, Harkness TA. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther. 2009;3:79–88.
   Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–385.
   PubMed Web of Science ®Google Scholar
• Yeon CH, Pegram MD. Anti-ERBB2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23:391–409.
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–448.
   PubMed Web of Science ®Google Scholar
• Harari D, Tzahar T, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ERBB-4 receptor tyrosine kinase. Oncogene. 1999;18:2681–2689.
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ERBB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998;18:6090–6101.
   PubMed Web of Science ®Google Scholar
• Nakano N, Higashiyama S, Kajihara K, et al. NTAKalpha and beta isoforms stimulate breast tumor cell growth by means of different receptor combinations. J Biochem. 2000;127:925–930.
   Web of Science ®Google Scholar
• Hijazi MM, Young PE, Dougherty MK, et al. NRG-3 in human breast cancers: activation of multiple ERBB family proteins. Int J Oncol. 1998;13:1061–1067.
   PubMed Web of Science ®Google Scholar